TScan Therapeutics, Inc. (TCRX)

NGM – Цена в реальном времени. Валюта: USD

0.76

-0.01 (-1.61%)

Рынок открыт: Aug 12, 2026, 3:10 PM EDT

0.80

+0.02 (2.85%)

Предыдущая сессия: Aug 11, 2026, 5:59 PM EDT

12.08.2026

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.

12.08.2026

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended June 30, 2026, and provided a corporate update.

Видео

No Data

There is no data to display

Пресс-релизы

12.08.2026

TScan Therapeutics, Inc. (TCRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

TScan Therapeutics, Inc. (TCRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update